Ascendis Pharma A/S vs KLA Corp. — how do they compare? Ascendis Pharma A/S trades at $255.5 (market cap $16.67B), while KLA Corp. trades at $208.6 (market cap $261.92B). The key difference: KLA Corp. is far larger — about 15.7× Ascendis Pharma A/S's market cap, and KLA Corp. pays a 0.46% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | KLAC | |
|---|---|---|
Market Cap | $16.67B | $261.92B |
Sector | Health | Technology |
52-Week High | $277.18 | $301.71 |
52-Week Low | $189.74 | $84.39 |
Enterprise Value | $17.04B | $263.17B |
Dividend Yield | — | 0.46% |
Trailing returns across standard periods
Latest headlines on both assets
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →